Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-κB and ERK activation

FEBS Lett. 2011 Sep 2;585(17):2755-62. doi: 10.1016/j.febslet.2011.07.046. Epub 2011 Aug 6.


Osteolytic bone diseases including osteoporosis are commonly accompanied with enhanced osteoclast formation and bone resorption. Naringin, a natural occurring flavonoid has been found to protect against retinoic acid-induced osteoporosis and improve bone quality in rats. Here, we showed that naringin perturbs osteoclast formation and bone resorption by inhibiting RANK-mediated NF-κB and ERK signaling. Naringin suppressed gene expression of key osteoclast marker genes. Naringin was found to inhibit RANKL-induced activation of NF-κB by suppressing RANKL-mediated IκB-α degradation. In addition, naringin inhibited RANKL-induced phosphorylation of ERK. This study identifies naringin as an inhibitor for osteoclast formation and bone resorption, and provides evidence that natural compounds such as naringin might be beneficial as an alternative medicine for the prevention and treatment of osteolysis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Apoptosis / genetics
  • Blotting, Western
  • Bone Resorption / genetics
  • Bone Resorption / metabolism*
  • Cell Line
  • Enzyme Activation / drug effects
  • Extracellular Signal-Regulated MAP Kinases / metabolism*
  • Flavanones / pharmacology*
  • Mice
  • Microscopy, Confocal
  • NF-kappa B / metabolism*
  • Osteoclasts / cytology
  • Osteoclasts / drug effects*
  • Osteoclasts / metabolism*
  • Osteogenesis / drug effects*
  • Osteogenesis / genetics
  • RANK Ligand / pharmacology*
  • Rats
  • Reverse Transcriptase Polymerase Chain Reaction


  • Flavanones
  • NF-kappa B
  • RANK Ligand
  • Extracellular Signal-Regulated MAP Kinases
  • naringin